Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning onset of effect study of Symbicort versus Seretide in severe COPD
2007-001337-34Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of budesonide and salmeterol + fluticasone in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Peak expiratory flow 5 minutes after morning dose. Started Jun 2007; status: completed.
02
Drugs
budesonidesalmeterol + fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2007-001337-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001337-34.